Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.76
CBM's Cash to Debt is ranked higher than
55% of the 1270 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CBM: 0.76 )
CBM' s 10-Year Cash to Debt Range
Min: 0.04   Max: 0.76
Current: 0.76

0.04
0.76
Equity to Asset 0.52
CBM's Equity to Asset is ranked higher than
65% of the 968 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBM: 0.52 )
CBM' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.57
Current: 0.52

0.22
0.57
F-Score: 7
Z-Score: 3.71
M-Score: -2.36
WACC vs ROIC
8.62%
25.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.96
CBM's Operating margin (%) is ranked higher than
90% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. CBM: 13.96 )
CBM' s 10-Year Operating margin (%) Range
Min: -2.77   Max: 18.02
Current: 13.96

-2.77
18.02
Net-margin (%) 15.30
CBM's Net-margin (%) is ranked higher than
91% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -78.17 vs. CBM: 15.30 )
CBM' s 10-Year Net-margin (%) Range
Min: -98.33   Max: 82.87
Current: 15.3

-98.33
82.87
ROE (%) 25.07
CBM's ROE (%) is ranked higher than
96% of the 1154 Companies
in the Global Biotechnology industry.

( Industry Median: -34.19 vs. CBM: 25.07 )
CBM' s 10-Year ROE (%) Range
Min: -94.37   Max: 120.02
Current: 25.07

-94.37
120.02
ROA (%) 12.40
CBM's ROA (%) is ranked higher than
95% of the 1274 Companies
in the Global Biotechnology industry.

( Industry Median: -27.54 vs. CBM: 12.40 )
CBM' s 10-Year ROA (%) Range
Min: -37.93   Max: 42.71
Current: 12.4

-37.93
42.71
ROC (Joel Greenblatt) (%) 20.99
CBM's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 1243 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. CBM: 20.99 )
CBM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3.31   Max: 32.71
Current: 20.99

-3.31
32.71
Revenue Growth (3Y)(%) 11.00
CBM's Revenue Growth (3Y)(%) is ranked higher than
85% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CBM: 11.00 )
CBM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -18   Max: 11
Current: 11

-18
11
EBITDA Growth (3Y)(%) 14.90
CBM's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -4.50 vs. CBM: 14.90 )
CBM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27   Max: 32.8
Current: 14.9

-27
32.8
EPS Growth (3Y)(%) 58.70
CBM's EPS Growth (3Y)(%) is ranked higher than
97% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. CBM: 58.70 )
CBM' s 10-Year EPS Growth (3Y)(%) Range
Min: -21.5   Max: 79.7
Current: 58.7

-21.5
79.7
» CBM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CBM Guru Trades in Q1 2014

Paul Tudor Jones 18,500 sh (-4.65%)
Jim Simons 470,525 sh (-25.74%)
Chuck Royce 951,854 sh (-37.66%)
» More
Q2 2014

CBM Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
Chuck Royce 801,354 sh (-15.81%)
Jim Simons 328,200 sh (-30.25%)
» More
Q3 2014

CBM Guru Trades in Q3 2014

Chuck Royce 921,629 sh (+15.01%)
Jim Simons 261,500 sh (-20.32%)
» More
Q4 2014

CBM Guru Trades in Q4 2014

Paul Tudor Jones 17,728 sh (New)
Joel Greenblatt 78,575 sh (New)
Chuck Royce 956,112 sh (+3.74%)
Jim Simons 154,600 sh (-40.88%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 New Buy0.01%$16.33 - $24.12 $ 34.462%78575
Joel Greenblatt 2013-03-31 Sold Out 0.09%$11.27 - $12.79 $ 34.4188%0
Joel Greenblatt 2012-12-31 New Buy0.09%$9.34 - $13.96 $ 34.4202%142352
Joel Greenblatt 2012-09-30 Sold Out 0.02%$9.01 - $13.01 $ 34.4211%0
Joel Greenblatt 2012-06-30 New Buy0.02%$5.96 - $9.16 $ 34.4387%30208
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.00
CBM's P/E(ttm) is ranked higher than
97% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 19.00 )
CBM' s 10-Year P/E(ttm) Range
Min: 1.05   Max: 63.2
Current: 19

1.05
63.2
Forward P/E 19.76
CBM's Forward P/E is ranked higher than
95% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 19.76 )
N/A
PE(NRI) 18.60
CBM's PE(NRI) is ranked higher than
97% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 18.60 )
CBM' s 10-Year PE(NRI) Range
Min: 5.17   Max: 129.95
Current: 18.6

5.17
129.95
P/B 4.40
CBM's P/B is ranked higher than
78% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 6.64 vs. CBM: 4.40 )
CBM' s 10-Year P/B Range
Min: 0.61   Max: 5.22
Current: 4.4

0.61
5.22
P/S 2.80
CBM's P/S is ranked higher than
94% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 30.34 vs. CBM: 2.80 )
CBM' s 10-Year P/S Range
Min: 0.18   Max: 10.71
Current: 2.8

0.18
10.71
PFCF 26.20
CBM's PFCF is ranked higher than
96% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 26.20 )
CBM' s 10-Year PFCF Range
Min: 4.81   Max: 245.33
Current: 26.2

4.81
245.33
POCF 16.65
CBM's POCF is ranked higher than
97% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 16.65 )
CBM' s 10-Year POCF Range
Min: 2.94   Max: 65
Current: 16.65

2.94
65
EV-to-EBIT 14.61
CBM's EV-to-EBIT is ranked higher than
96% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 14.61 )
CBM' s 10-Year EV-to-EBIT Range
Min: -2271   Max: 388.4
Current: 14.61

-2271
388.4
PEG 1.22
CBM's PEG is ranked higher than
99% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 1.22 )
CBM' s 10-Year PEG Range
Min: 0.52   Max: 42.7
Current: 1.22

0.52
42.7
Shiller P/E 35.40
CBM's Shiller P/E is ranked higher than
98% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 35.40 )
CBM' s 10-Year Shiller P/E Range
Min: 5.64   Max: 141.6
Current: 35.4

5.64
141.6
Current Ratio 2.30
CBM's Current Ratio is ranked higher than
63% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CBM: 2.30 )
CBM' s 10-Year Current Ratio Range
Min: 1.72   Max: 3.48
Current: 2.3

1.72
3.48
Quick Ratio 1.44
CBM's Quick Ratio is ranked higher than
59% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CBM: 1.44 )
CBM' s 10-Year Quick Ratio Range
Min: 0.88   Max: 2
Current: 1.44

0.88
2
Days Inventory 139.34
CBM's Days Inventory is ranked higher than
86% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 139.34 )
CBM' s 10-Year Days Inventory Range
Min: 107.67   Max: 228.78
Current: 139.34

107.67
228.78
Days Sales Outstanding 75.14
CBM's Days Sales Outstanding is ranked higher than
79% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 116.17 vs. CBM: 75.14 )
CBM' s 10-Year Days Sales Outstanding Range
Min: 49.84   Max: 112.79
Current: 75.14

49.84
112.79

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.40
CBM's Price/Tangible Book is ranked higher than
80% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. CBM: 5.40 )
CBM' s 10-Year Price/Tangible Book Range
Min: 2.02   Max: 12.46
Current: 5.4

2.02
12.46
Price/DCF (Projected) 2.70
CBM's Price/DCF (Projected) is ranked higher than
96% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 2.70 )
CBM' s 10-Year Price/DCF (Projected) Range
Min: 1.03   Max: 9.84
Current: 2.7

1.03
9.84
Price/Median PS Value 2.30
CBM's Price/Median PS Value is ranked higher than
73% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. CBM: 2.30 )
CBM' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 2.57
Current: 2.3

0.43
2.57
Price/Peter Lynch Fair Value 1.50
CBM's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 1.50 )
CBM' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.77   Max: 3.58
Current: 1.5

0.77
3.58
Price/Graham Number 2.10
CBM's Price/Graham Number is ranked higher than
96% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CBM: 2.10 )
CBM' s 10-Year Price/Graham Number Range
Min: 0.43   Max: 24.76
Current: 2.1

0.43
24.76
Earnings Yield (Greenblatt) 6.50
CBM's Earnings Yield (Greenblatt) is ranked higher than
95% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CBM: 6.50 )
CBM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 222.1
Current: 6.5

0.3
222.1
Forward Rate of Return (Yacktman) 13.83
CBM's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 167 Companies
in the Global Biotechnology industry.

( Industry Median: 15.69 vs. CBM: 13.83 )
CBM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -42.4   Max: 21
Current: 13.83

-42.4
21

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XBX.Germany,
Cambrex Corp was incorporated as a Delaware corporation in 1981 and began business in December 1981. It is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company participates in markets that serve the healthcare industry. Customers include generic drug companies and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The Company uses its technical expertise in a wide range of chemical processes to meet the needs of its customers for high quality products and services for specialized applications. The Company's business is primarily comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products and services are supplied globally to innovator and generic drug companies. Products include APIs, pharmaceutical intermediates and, to a lesser extent, other fine chemicals. The Company's products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc. The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, the European Medicines Agency and comparable regulatory authorities in other countries.
» More Articles for CBM

Headlines

Articles On GuruFocus.com
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 


More From Other Websites
Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog Feb 26 2015
Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog Feb 26 2015
Integra Lifesciences Tops Q4 Earnings, Revenues; Up Y/Y - Analyst Blog Feb 25 2015
China Biologic Products CBPO) Falls: Stock Goes Down 6% - Tale of the Tape Feb 25 2015
Exact Sciences (EXAS) Falls: Stock Goes Down 5.6% - Tale of the Tape Feb 24 2015
Innovation Alive And Well In Medical-Products Group Feb 19 2015
Will Cambrex (CBM) Continue to Surge Higher? - Tale of the Tape Feb 19 2015
Oncolytics' Reolysin Gets Another Orphan Drug Status - Analyst Blog Feb 18 2015
Zacks Rank #1 Additions for Wednesday - Tale of the Tape Feb 18 2015
Increased Earnings Estimates Seen for Cambrex Corporation (CBM): Can It Move Higher? - Tale of the... Feb 18 2015
CAMBREX CORP Financials Feb 12 2015
4 Top Stocks to Buy on Earnings Beats and Raised Guidance Feb 10 2015
Cambrex (CBM) Worth Watching: Stock Soars 27.5% - Tale of the Tape Feb 09 2015
10-K for Cambrex Corp. Feb 08 2015
Stocks Slump In Closing Hour On Greek Jitters Feb 06 2015
Cambrex Corp Earnings Call scheduled for 8:30 am ET today Feb 06 2015
CAMBREX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 06 2015
Cambrex Announces Expansion of Large Scale API Capacity Feb 06 2015
Cambrex Reports Fourth Quarter And Full Year 2014 Financial Results Feb 06 2015
Q4 2014 Cambrex Corp Earnings Release - Before Market Open Feb 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK